Business context and reporting period
Entity discrepancy: The request identifies Tectonic Therapeutic, Inc., but the supplied Form 10-Q is for AVROBIO, Inc. It covers the quarter and six months ended June 30, 2018; the filing was signed August 9, 2018.
AVROBIO was a clinical-stage gene-therapy company developing ex vivo lentiviral therapies for rare diseases. It had no approved products and generated no product revenue. Its lead program, AVR-RD-01 for Fabry disease, had recently dosed its first patient in a company-sponsored Phase 2 trial.
Financial results and liquidity
Amounts below are in millions of dollars except per-share data. As a development-stage company without product sales, AVROBIO reported operating expenses and losses rather than revenue or operating margins.
| Metric | Q2 2018 | Q2 2017 | Six months 2018 | Six months 2017 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development | $7.407 | $1.881 | $13.054 | $3.315 |
| General and administrative | $2.140 | $0.661 | $4.281 | $1.271 |
| Total operating expenses | $9.547 | $2.542 | $17.335 | $4.586 |
| Net loss | $(10.507) | $(2.534) | $(18.749) | $(4.611) |
| Basic and diluted net loss per share | $(2.98) | $(1.15) | $(7.16) | $(2.12) |
| Operating cash used | Not provided for quarter | Not provided for quarter | $(14.229) | $(4.458) |
At June 30, cash and cash equivalents were $155.015 million, compared with $5.963 million at December 31, 2017. Total current assets were $156.147 million and current liabilities $9.631 million. The filing reports no drawn debt; $10 million remained available under a milestone- and condition-dependent secured loan facility. Cash provided by financing in the first half was $163.681 million, mainly from the IPO and January Series B preferred-stock financing. No gross margin is meaningful or reported.
Material changes versus the prior comparable period
- Q2 operating expenses rose $7.005 million year over year, while net loss widened $7.973 million. For the first half, operating expenses increased $12.749 million and net loss widened $14.138 million.
- Higher R&D reflected increased Fabry and Gaucher program activity, development and manufacturing costs, and personnel and facility growth. G&A also increased with hiring, public-company preparation and professional services.
- First-half operating cash use increased by $9.771 million year over year. The company funded operations with $58.258 million net proceeds from Series B preferred stock and $105.423 million net IPO proceeds, as shown in the cash-flow statement.
- The June IPO raised aggregate net proceeds of approximately $104.2 million according to the notes and Part II; preferred stock converted into common stock at closing. The company also approved a 1-for-4.312 reverse stock split in June; share and per-share data are retrospectively adjusted.
Outlook, risks, contingencies and unusual items
- Management expected June 30 cash to fund operating expenses and capital expenditures into 2020, while cautioning that assumptions could prove wrong. It expected substantial expense increases as trials, manufacturing development, hiring and public-company costs continued; additional funding may be needed.
- Management reported a recent FDA pre-IND meeting for AVR-RD-01 and expected to open a U.S. site for its ongoing Phase 2 trial in 2019. A third patient was dosed in the investigator-sponsored Phase 1 trial on July 11, 2018. These are forward-looking or post-quarter developments, not completed outcomes.
- A $2.0 million UHN IPO dilution payment was accrued at June 30 and paid in July. Its fair-value remeasurement contributed $1.042 million of Q2 expense and $1.629 million of first-half expense. The preferred-stock warrant fair-value change added $0.150 million and $0.162 million of expense, respectively.
- The company had no material legal proceedings reported. License agreements carry potential future milestone, royalty and sublicense-payment obligations; the filing said no such payments were expected in the immediate future. A new Cambridge lease runs through January 2023, with annual payment increases of 3%.
- Controls concern: Management concluded disclosure controls were not effective at June 30 because previously disclosed material weaknesses remained in financial close and cash-disbursement controls. A 2017 cyberattack resulted in theft of a portion of funds. Remediation was underway, with no assurance it would succeed.
- Key risks include clinical efficacy, safety and enrollment; gene-therapy regulation; manufacturing and third-party supplier dependence; intellectual-property and license rights; competition; future financing and dilution; and the possibility of never achieving profitability. The company also disclosed foreign-currency exposure, but said a 10% exchange-rate change was not expected to have a material impact.
Most important facts for investors to verify
- Confirm the filing is AVROBIO’s, not Tectonic Therapeutic’s, before attributing any figures or developments to the requested company.
- Track cash burn against the stated runway into 2020, including the $2.0 million post-quarter UHN payment and planned clinical and manufacturing spending.
- Verify subsequent AVR-RD-01 trial enrollment, safety and efficacy updates, U.S. site timing, and regulatory requirements; the filing provides no evidence of later trial outcomes.
- Monitor remediation and independent validation of the disclosed material weaknesses in financial reporting and cash disbursement controls.
- Review the loan facility’s draw conditions and restrictions, future capital needs, potential dilution, and material license and manufacturing commitments.